XML 28 R14.htm IDEA: XBRL DOCUMENT

8. INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

The carrying values of the Company’s finite-lived intangible assets were as follows:

	September 30, 2020							December 31, 2019
			Accumulated							Accumulated
	Cost		Amortization			Net		Cost		Amortization			Net
Patent	$	510,310	$	(510,310	)	$	-	$	510,310	$	(510,310	)	$	-
Licenses		3,350,000		(202,268	)		3,147,732		1,500,000		(48,876	)		1,451,124
Software and Other		64,464		(50,015	)		14,449		64,464		(44,394	)		20,070
Total	$	3,924,774	$	(762,593	)	$	3,162,181	$	2,074,774	$	(603,580	)	$	1,471,194

During the first quarter of 2020, the Company paid a $500,000 milestone payment to Rochal upon FDA clearance of BIAKŌS™ Antimicrobial Wound Gel pursuant to the terms of the BIAKŌS™ License Agreement. The milestone payment was recorded as an addition to intangible assets. During the second quarter of 2020, the Company entered into the Debrider License Agreement which required an initial payment of $1,350,000 to Rochal which consisted of $600,000 in cash and $750,000 in the Company’s common stock.

As of September 30, 2020, the weighted-average amortization period for all intangible assets is 12.8 years. Amortization expense related to intangible assets was $159,013 for the nine months ended September 30, 2020 and $55,763 for the nine months ended September 30, 2019. The estimated remaining amortization expense as of September 30, 2020 is as follows:

Remainder of 2020	$	64,515
2021		258,059
2022		255,645
2023		250,564
2024		250,564
Thereafter		2,082,834
Total	$	3,162,181

The Company has reviewed the carrying value of intangible assets due to the events and circumstances surrounding the COVID-19 pandemic. The Company does not believe the impact of COVID-19 has created an impairment loss on the Company’s intangible assets as of September 30, 2020. Accordingly, there was no impairment loss recognized on the Company’s intangible assets during the nine months ended September 30, 2020.